Tecan and Attana Extend Distribution Agreement
News Oct 14, 2011
Tecan and Attana AB have announced an extended distribution agreement under which Tecan will distribute Attana's label-free biosensor instruments and quartz crystal microbalance (QCM) assay technology in Europe.
This collaboration covers the Attana 100, Attana 200 and Cell 200 instruments, as well as biosensors and assay reagents, service and support, extending the existing agreement for North America announced earlier this year.
Exceptions to this agreement are Scandinavia and those countries covered by Tecan’s distributor network.
This distribution agreement will ensure customers in these new markets can take advantage of QCM technology for analysis of molecular interactions in a wide variety of research applications, supported by Tecan’s sales, service and applications capabilities.
“We are pleased to announce this expansion only six months after our initial agreement with Tecan for North America,” commented Teodor Aastrup, CEO and founder of Attana.
Aastrup continued, “This collaboration will strengthen Attana’s position in Europe through Tecan’s broad sales channels and local presence. Our products complement each other well, and we are able to offer customers a complete solution for biomolecular investigation.”
Andrea Becarri, Global Head of Commercial, at Tecan, added: “Extension of our agreement with Attana will ensure customers receive the highest level of support for their applications, helping them to make the most of this innovative technology with the assistance of Tecan’s knowledgeable sales and service personnel.”
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018